Engineering of the endogenous HBD promoter increases HbA2
eLife · 2023
DOI: 10.7554/elife.85258 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Mandy Y Boontanrart und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, ETH Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: delta-Globins, Hemoglobinopathies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, ETH Zürich Foundation, SNSF.
Abstract (Originalsprache)
The β-hemoglobinopathies, such as sickle cell disease and β-thalassemia, are one of the most common genetic diseases worldwide and are caused by mutations affecting the structure or production of β-globin subunits in adult hemoglobin. Many gene editing efforts to treat the β-hemoglobinopathies attempt to correct β-globin mutations or increase γ-globin for fetal hemoglobin production. δ-globin, the subunit of adult hemoglobin A2, has high homology to β-globin and is already pan-cellularly expressed at low levels in adult red blood cells. However, upregulation of δ-globin is a relatively unexplored avenue to increase the amount of functional hemoglobin. Here, we use CRISPR-Cas9 to repair non-functional transcriptional elements in the endogenous promoter region of δ-globin to increase overall expression of adult hemoglobin 2 (HbA2). We find that insertion of a KLF1 site alone is insufficient to upregulate δ-globin. Instead, multiple transcription factor elements are necessary for robust upregulation of δ-globin from the endogenous locus. Promoter edited HUDEP-2 immortalized erythroid progenitor cells exhibit striking increases of HBD transcript, from less than 5% to over 20% of total β-like globins in clonal populations. Edited CD34 +hematopoietic stem and progenitors (HSPCs) differentiated to primary human erythroblasts express up to 46% HBD in clonal populations. These findings add mechanistic insight to globin gene regulation and offer a new therapeutic avenue to treat β-hemoglobinopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, ETH Zurich, Zurich, Switzerland.
ORCID-Profile: Simone Ponta, Jacob E Corn
Förderung
- NIDDK NIH HHS
- ETH Zürich Foundation
- SNSF
Zitieren
APA
Boontanrart, M. Y., Mächler, E., Ponta, S., Nelis, J. C., Preiano, V. G., & Corn, J. E. (2023). Engineering of the endogenous HBD promoter increases HbA2. eLife. https://doi.org/10.7554/elife.85258
Vancouver
Boontanrart MY, Mächler E, Ponta S, Nelis JC, Preiano VG, Corn JE. Engineering of the endogenous HBD promoter increases HbA2. eLife. 2023. doi:10.7554/elife.85258
BibTeX
@article{Boontanrart2023,
author = {Boontanrart, Mandy Y and Mächler, Elia and Ponta, Simone and Nelis, Jan C and Preiano, Viviana G and Corn, Jacob E},
title = {Engineering of the endogenous HBD promoter increases HbA2},
journal = {eLife},
year = {2023},
doi = {10.7554/elife.85258}
}
EUVIMED